---
title: The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
nct_id: NCT03377153
overall_status: UNKNOWN
phase: NA
sponsor: National Nutrition and Food Technology Institute
study_type: INTERVENTIONAL
primary_condition: Non Alcoholic Steatohepatitis
countries: Iran
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03377153.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03377153"
ct_last_update_post_date: 2017-12-19
last_seen_at: "2026-05-12T07:11:48.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

**Official Title:** Evaluation of the Effects of Hesperidin and Flaxseed Supplementation on Hepatic Enzymes, Inflammatory Factors, Lipid Profile, Blood Glucose, Insulin Sensitivity, and Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease

**NCT ID:** [NCT03377153](https://clinicaltrials.gov/study/NCT03377153)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** National Nutrition and Food Technology Institute
- **Conditions:** Non Alcoholic Steatohepatitis
- **Start Date:** 2017-06-01
- **Completion Date:** 2018-03-20
- **CT.gov Last Update:** 2017-12-19

## Brief Summary

To study the effects of Hesperidin and flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI) clinic with steatosis grade 2 and 3 will be randomly allocated to contol group or 2 capsules Hesperidin and 30 gram flaxseed for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. At the first and the end of the intervention, lipid profiles, liver enzymes, some inflammatory markers, and liver fibrosis will be assessed and compared between groups.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

\- Age of 18 to 70 years

* Body Mass Index (BMI) between 25-40
* Sonographic findings compatible with hepatic steatosis (degree 2 or more)

Exclusion Criteria:

* Diabetes
* Taking any kind of antibiotics two weeks before recruitment
* History of alcohol consumption
* pregnancy or lactation
* Professional athletes
* Other liver disease (viral/etc)
* Use of drugs such as calcium channel blockers, high dose synthetic estrogens, methotrexate , amiodarone, steroids, chloroquine, immunosuppressive drugs, lipid-lowering agents, metformin and vitamin E
* A history of Hypertension, Cardiovascular disease, Pulmonary disease, Renal disease \& Celiac disease; Cirrhosis
* History of Upper GI surgery / Prior surgical procedures such as jejunoileal or jejunocolic bypass, gastroplasty
* Following program to lose weight in recent 3 mo
* A history of hypothyroidism or Cushing's syndrome
```

## Arms

- **Hesperidin and Flaxseed** (ACTIVE_COMPARATOR)
- **control** (PLACEBO_COMPARATOR)

## Interventions

- **hesperidin and flaxseed** (DIETARY_SUPPLEMENT) — 2 capsuls hesperidin and 30 g flaxseed
- **control** (OTHER) — no supplementation

## Primary Outcomes

- **liver fibrosis** _(time frame: 12 weeks)_ — assess by fibroscan

## Secondary Outcomes

- **body mass index** _(time frame: 12 weeks)_

## Locations (1)

- National Nutrition and Food Technology Research Institute, Tehran, Iran — _RECRUITING_

## Recent Field Changes (last 30 days)

- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.national nutrition and food technology research institute|tehran||iran` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03377153.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03377153*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*